← Leaderboards
Chendil Damodaran
Texas A&M University Health Science Ctr
$13,213,142
Attributed
$16,406,875
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2007–25$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,406,875 · 10
By mechanism
R01$16,088,731 · 9
R21$318,144 · 1
Top collaborators
- Arun K Sharma6 shared
- Jonathan H Freedman4 shared
- Adegboyega Oyelere4 shared
- Murali Ankem2 shared
Most similar at Texas A&M University Health Science Ctr
Same institution · by research overlap
- Arun K Sharma$2,620,326
- Murali Ankem$298,621
Others in their field
Top investigators on “Tumor Tissue”
- David Heimbrook · Leidos Biomedical Research, Inc.$329,212,748
- Timothy J Eberlein · Washington University$86,792,803
- Larry Arthur$85,804,691
- Richard L Schilsky · University Of Chicago$80,448,107
- Monica M Bertagnolli · Strang Cancer Prevention Center$75,743,395
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$72,731,981
Research focus
Tumor TissueMolecularIn VitroSignal TransductionTumor GrowthCellsMediatingBaseGrowthMalignant Neoplasm Of ProstateIn VivoPatternApoptosisXenograft ProcedureInsightLeadTumorProteinsDoseResistanceProstateSerumCancer CellCell Death
Grant awards (47)
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer$549,548
R01 · FY2025 · CA
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$450,179
R01 · FY2025 · CA · contact PI
Cell Survival Advantage in Cadmium Induced Carcinogenesis$439,782
R01 · FY2025 · ES · contact PI
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer$535,890
R01 · FY2024 · CA
Elucidating the molecular signaling of Cadmium Carcinogenesis$485,844
R01 · FY2024 · ES · contact PI
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$432,829
R01 · FY2024 · CA · contact PI
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer$539,006
R01 · FY2023 · CA
Elucidating the molecular signaling of Cadmium Carcinogenesis$499,532
R01 · FY2023 · ES · contact PI
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$448,531
R01 · FY2023 · CA · contact PI
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer$570,229
R01 · FY2022 · CA
Elucidating the molecular signaling of Cadmium Carcinogenesis$510,684
R01 · FY2022 · ES · contact PI
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$448,534
R01 · FY2022 · CA · contact PI
Cell Survival Advantage in Cadmium Induced Carcinogenesis$441,370
R01 · FY2022 · ES · contact PI
The role of autophagy in cadmium induced prostate carcinogenesis$342,564
R01 · FY2022 · ES · contact PI
Cell Survival Advantage in Cadmium Induced Carcinogenesis$440,953
R01 · FY2021 · ES · contact PI
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$395,105
R01 · FY2021 · CA · contact PI
The role of autophagy in cadmium induced prostate carcinogenesis$382,018
R01 · FY2021 · ES · contact PI
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer$1
R01 · FY2021 · CA · contact PI
Cell Survival Advantage in Cadmium Induced Carcinogenesis$469,962
R01 · FY2020 · ES · contact PI
The role of autophagy in cadmium induced prostate carcinogenesis$383,328
R01 · FY2020 · ES · contact PI
Cell Survival Advantage in Cadmium Induced Carcinogenesis$469,962
R01 · FY2019 · ES · contact PI
The role of autophagy in cadmium induced prostate carcinogenesis$399,036
R01 · FY2019 · ES · contact PI
Chemoprevention of metastatic colorectal cancer$420,338
R01 · FY2018 · CA · contact PI
The role of autophagy in cadmium induced prostate carcinogenesis$383,328
R01 · FY2018 · ES · contact PI
Chemoprevention of metastatic colorectal cancer$399,789
R01 · FY2017 · CA · contact PI
Chemoprevention of metastatic colorectal cancer$399,705
R01 · FY2016 · CA · contact PI
Chemoprevention of metastatic colorectal cancer$399,695
R01 · FY2015 · CA · contact PI
Targeting AR and Akt for the Treatment of Prostate Cancer$301,913
R01 · FY2015 · CA · contact PI
Dietary prevention of prostate cancer$301,911
R01 · FY2015 · CA · contact PI
Chemoprevention of metastatic colorectal cancer$412,244
R01 · FY2014 · CA · contact PI
Dietary prevention of prostate cancer$275,285
R01 · FY2014 · CA · contact PI
Targeting AR and Akt for the Treatment of Prostate Cancer$275,285
R01 · FY2014 · CA · contact PI
Dietary prevention of prostate cancer$1
R01 · FY2013 · CA · contact PI
Targeting AR and Akt for the Treatment of Prostate Cancer$1
R01 · FY2013 · CA · contact PI
Targeting AR and Akt for the Treatment of Prostate Cancer$298,893
R01 · FY2012 · CA · contact PI
Dietary prevention of prostate cancer$298,893
R01 · FY2012 · CA · contact PI
Targeting AR and Akt for the Treatment of Prostate Cancer$298,893
R01 · FY2011 · CA · contact PI
Dietary prevention of prostate cancer$298,893
R01 · FY2011 · CA · contact PI
Targeting Signaling to Prevent Colon Cancer$140,288
R21 · FY2011 · CA · contact PI
Targeting Signaling to Prevent Colon Cancer$16,362
R21 · FY2011 · CA · contact PI
Dietary prevention of prostate cancer$308,138
R01 · FY2010 · CA · contact PI
Targeting AR and Akt for the Treatment of Prostate Cancer$308,138
R01 · FY2010 · CA · contact PI
Targeting Signaling to Prevent Colon Cancer$161,494
R21 · FY2010 · CA · contact PI
Novel Herbal Medicine for the Treatment of Prostate Cancer$325,436
R01 · FY2009 · AT · contact PI
Novel Herbal Medicine for the Treatment of Prostate Cancer$29,205
R01 · FY2009 · AT · contact PI
Novel Herbal Medicine for the Treatment of Prostate Cancer$355,097
R01 · FY2008 · AT · contact PI
Novel Herbal Medicine for the Treatment of Prostate Cancer$362,763
R01 · FY2007 · AT · contact PI